Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) saw a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 11,400 shares, an increase of 570.6% from the March 15th total of 1,700 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 28,600 shares, the short-interest ratio is presently 0.4 days.
Novozymes A/S Price Performance
Shares of Novozymes A/S stock traded down $0.75 during midday trading on Monday, hitting $61.02. 37,148 shares of the company were exchanged, compared to its average volume of 32,741. The firm has a 50 day simple moving average of $58.38 and a 200-day simple moving average of $59.54. The firm has a market cap of $28.58 billion, a P/E ratio of 38.62, a PEG ratio of 3.87 and a beta of 0.91. Novozymes A/S has a 52 week low of $52.96 and a 52 week high of $72.50.
Novozymes A/S Increases Dividend
The company also recently disclosed a dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Monday, April 7th will be paid a dividend of $0.3758 per share. This is a boost from Novozymes A/S’s previous dividend of $0.17. The ex-dividend date is Monday, April 7th. Novozymes A/S’s dividend payout ratio is currently 47.47%.
About Novozymes A/S
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.
Featured Stories
- Five stocks we like better than Novozymes A/S
- What is a Stock Market Index and How Do You Use Them?
- Why NVIDIA Stock Could Soar Despite Wall Street Downgrades
- Basic Materials Stocks Investing
- Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold
- Financial Services Stocks Investing
- 3 Hot New IPOs Defying the 2025 Market Slump
Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.